Kunwar Shailubhai, Ph.D., M.B.A. serves as Chief Executive Officer and Chief Scientific Officer of Tiziana Life Sciences, and is also an Executive Director of the Company. Dr. Shailubhai brings more than 25 years of experience within the life science industry, combined with a distinguished track record of success in translating drugs from concept through commercialisation to market. He also currently serves as CEO of Rasna Therapeutics, Inc., a developer of therapeutics  to address the high unmet need that exists for AML and other forms of leukemia.    Dr. Shailubhai has been serving as a member of board of Tiziana Life Sciences since 2015. He actively played key roles in development of growth strategies through several key licensings of technologies and drug candidates. Dr. Shailubhai steered the company through prioritisation of projects to focus on novel drug candidates for treatment of autoimmune and inflammatory diseases and cancer.

 As co-founder, EVP and CSO of Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) he led the non-clinical, CMC and clinical development of Trulance™ from inception to approval by the FDA, having co-invented and pioneered Synergy’s platform technology for functional GI disorders, inflammatory bowel disease, GI cancer and other human diseases.  Dr. Shailubhai as the chief architect of the IP estate, directed all aspects of IP management, including timely submission of patent applications, directing office actions and coordinating with IP attorneys.   Earlier, from 2003 until 2008, Dr. Shailubhai served as Senior Vice President, Drug Discovery and from 2001 to 2003, he held the position of Vice President, Drug Discovery at Synergy, where he pioneered therapeutic applications of GC-C agonists in a variety of human diseases such as Asthma, COPD and cholesterol lowering.   Prior to Synergy, he was with Monsanto Company, serving as Group Leader, Cancer Prevention and previously served as a Senior Staff Fellow at the National Institutes of Health, and as an Assistant Professor at the University of Maryland.   Dr. Shailubhai received his Ph.D. in microbiology from the University of Baroda, India, and his MBA from the University of Missouri, St. Louis. He has more than 20 issued patents and over 50 peer-reviewed publications.